By proceeding, you agree to our Terms of Use and Privacy Policy.
Adam Stefanski is currently working as Executive Director R&D Clinical Research at Eli Lilly and Company.
Talks About #clinicaleresearch #lecturing
Preferred Locations #Europe
The surge of clinical approvals in CKD and unprecedented use of surrogate endpoints in rare kidney diseases have catalysed a new era of complimentary therapies and precision medicine in drug development for kidney disease.
